Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AALL1131: Chemotherapy and Dasatinib in Newly Diagnosed High Risk B-ALL
NCT02883049Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2012
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of dasatinib, clofarabine, etoposide in B cell acute lymphoblastic leukemia (B-ALL), sponsored by National Cancer Institute. Started Feb 2012; status: completed.
02
Drugs
dasatinibclofarabineetoposide
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02883049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883049.